Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis

Journal of Infectious Diseases

Volumn 204, Issue 4, 2011, Pages 636-644

  Easton, Anna ^a   Ashraful Haque, ^b   Chu, Karen ^c   Patel, Natasha ^d   Lukaszewski, Roman A ^e   Krieg, Arthur M ^f   Titball, Richard W ^g   Bancroft, Gregory J ^d  

^a Centre for Medical Microbiology   (United Kingdom)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^f 400 Technology Square   (United States)

^g UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BURKHOLDERIA PSEUDOMALLEI VACCINE 2D2; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BURKHOLDERIA PSEUDOMALLEI; CELL SECRETION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNOTHERAPY; MELIOIDOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SEPSIS; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL VACCINES; BIOLOGICAL WARFARE AGENTS; BURKHOLDERIA PSEUDOMALLEI; CPG ISLANDS; FEMALE; LUNG; MELIOIDOSIS; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES;

EID: 79960875958     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir301     Document Type: Article

References (43)

1. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18:383-416. (Pubitemid 40548298)
2. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 2006; 4:272-82.
3. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005; 43:970-2. (Pubitemid 40256075)
4. Ip M, Osterberg LG, Chau PY, Raffin TA. Pulmonary melioidosis. Chest 1995; 108:1420-4.
5. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31:981-6. (Pubitemid 32299357)
6. Puthucheary SD, Vadivelu J, Wong KT, Ong GS. Acute respiratory failure in melioidosis. Singapore Med J 2001; 42:117-21. (Pubitemid 33705699)
7. Chan KP, Low JG, Raghuram J, Fook-Chong SM, Kurup A. Clinical characteristics and outcome of severe melioidosis requiring intensive care. Chest 2005; 128:3674-8. (Pubitemid 41698710)
8. Puthucheary SD, Parasakthi N, LeeMK. Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans R Soc Trop Med Hyg 1992; 86:683-5. (Pubitemid 23012937)
9. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocytedependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999; 162:2291-8. (Pubitemid 29288853)
10. Waag DM, McCluskie MJ, Zhang N, Krieg AM. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun 2006; 74:1944-8. (Pubitemid 43346833)
11. Wongratanacheewin S, Kespichayawattana W, Intachote P, et al. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun 2004; 72:4494-502. (Pubitemid 38989307)
12. Nelson M, Prior JL, Lever MS, Jones HE, Atkins TP, Titball RW. Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J Med Microbiol 2004; 53:1177-82. (Pubitemid 40052471)
13. Healey GD, Elvin SJ, Morton M, Williamson ED. Humoral and cellmediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect Immun 2005; 73:5945-51. (Pubitemid 41193033)
14. Chen YS, Hsiao YS, Lin HH, Yen CM, Chen SC, Chen YL. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 2006; 24:750-8.
15. Jones SM, Ellis JF, Russell P, Griffin KF, Oyston PC. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 2002; 51:1055-62. (Pubitemid 36020726)
16. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003; 171:1602-9. (Pubitemid 36900097)
17. Giri PK, Sable SB, Verma I, Khuller GK. Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. FEMS Immunol Med Microbiol 2005; 45:87-93. (Pubitemid 40848715)
18. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84. (Pubitemid 44136959)
19. Atkins T, Prior RG, Mack K, et al. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun 2002; 70:5290-4.
20. Vicari AP, Schmalbach T, Lekstrom-Himes J, et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic Toll-like receptor 9 agonist. Antivir Ther 2007; 12:741-51. (Pubitemid 47235488)
21. Easton A, Haque A, Chu K, Lukaszewski R, Bancroft GJ. A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 2007; 195:99-107. (Pubitemid 44958231)
22. Haque A, Chu K, Easton A, et al. A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis 2006; 194:1241-8. (Pubitemid 44630969)
23. Miyagi K, Kawakami K, Saito A. Role of reactive nitrogen and oxygen intermediates in gamma interferon-stimulated murine macrophage bactericidal activity against Burkholderia pseudomallei. Infect Immun 1997; 65:4108-3.
24. Lertmemongkolchai G, Cai G, Hunter CA, Bancroft GJ. Bystander activation of CD8+T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J Immunol 2001; 166:1097-105. (Pubitemid 32060268)
25. Stevens DL. Bacterial shock: clinical definitions, clinical trials and the dynamics of the host response. Curr Opin Infect Dis 2001; 14:247-9. (Pubitemid 32493533)
26. Simpson AJ, Smith MD, Weverling GJ, et al. Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis 2000; 181:621-5. (Pubitemid 30131830)
27. Liu B, Koo GC, Yap EH, Chua KL, Gan YH. Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect Immun 2002; 70:504-11. (Pubitemid 34083807)
28. Leakey AK, Ulett GC, Hirst RG. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathog 1998; 24:269-75. (Pubitemid 28266810)
29. Levine HB, Maurer RL. Immunization with an induced avirulent auxotrophic mutant of Pseudomonas pseudomallei. J Immunol 1958; 81:433-8.
30. Dannenberg AM Jr, Scott EM. Melioidosis: pathogenesis and immunity in mice and hamsters. III. Effect of vaccination with avirulent strains of Pseudomonas pseudomallei on the resistance to the establishment and the resistance to the progress of respiratory melioidosis caused by virulent strains; all-or-none aspects of this disease. J Immunol 1960; 84:233-46.
31. Breitbach K, Kohler J, Steinmetz I. Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans R Soc Trop Med Hyg 2008; 102(Suppl 1):S89-94.
32. Breitbach K, Klocke S, Tschernig T, van Rooijen N, Baumann U, Steinmetz I. Role of inducible nitric oxide synthase and NADPH oxidase in the early control of Burkholderia pseudomallei infection in mice. Infect Immun 2006; 74:6300-9. (Pubitemid 44657411)
33. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998; 161:2428-34. (Pubitemid 28397058)
34. Juffermans NP, Leemans JC, Florquin S, et al. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun 2002; 70:147-52. (Pubitemid 34028611)
35. Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol 2004; 173:5148-55. (Pubitemid 39402952)
36. Rees DG, Gates AJ, Green M, et al. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Antivir Res 2005; 65:87-95. (Pubitemid 40222285)
37. Friedland JS, Suputtamongkol Y, Remick DG, et al. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun 1992; 60:2402-8.
38. Vietri NJ, Purcell BK, Lawler JV, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A 2006; 103:7813-6.
39. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother 2004; 48:4513-9. (Pubitemid 39577647)
40. Tormo D, Ferrer A, Bosch P, et al. Therapeutic efficacy of antigenspecific vaccination and Toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006; 66:5427-35. (Pubitemid 43844970)
41. Burke DS. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratoryacquired tularemia. J Infect Dis 1977; 135:55-60.
42. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763-3.
43. Propst KL, Troyer RM, Kellihan LM, Schweizer HP, Dow SW. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother 2010; 54:1785-92.